Clinical Trial Update: A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating AUY922 (an Hsp90 inhibitor) in combination with capecitabine for metastatic or unresectable solid tumors has completed with posted resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Unresectable Solid Tumor Malignancy

Drugs mentioned

• AUY922 (luminespib)
• Capecitabine (capecitabine)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Metastatic or Unresectable Solid Tumor Malignancy | Phase 1 | Status: COMPLETED | Results posted: 2015-01-14